Efficacy of Drug and Risk Counseling Among Methadone Patients in Jakarta, Indonesia

NCT01360463 | Completed Phase 2

• 2 other identifiers: JAKPROR01DA026344
• Study Type: interventional
• Target: 276
• Locations: 1 country
• Sites: 1

Brief Summary

According to UNAIDS, Indonesia is experiencing one of the most rapidly expanding HIV/AIDS epidemics in Asia. The epidemic in Indonesia has been fueled by injection drug use among heroin users and the national response includes the scale-up of methadone maintenance treatment. Drug counseling is considered to be an integral part of methadone treatment, but few studies have been designed to assess its benefits and costs. In settings such as Jakarta, data regarding the costs and benefits of drug counseling have critical public heath relevance. The investigators propose to conduct a prospective randomized trial to evaluate the efficacy of integrated drug and HIV counseling among injecting drug users. This study will be conducted at six methadone clinics in Jakarta, Indonesia where the HIV prevalence among injecting drug users ranges between 50- 86%, with collaborators from the Drug Dependence Hospital in Jakarta, the University of Pennsylvania and Yale University. The specific aims of this four year study are to evaluate the impact of Behavioral Drug and Risk Counseling (BDRC)-a low intensity, cognitive behavioral approach that integrates drug counseling and risk reduction intervention. Those assigned to the BDRC arm will be compared to those who receive treatment as usual which includes an initial risk reduction intervention and counseling as needed. The investigators hypothesize that the structured, low intensity BDRC approach will be more cost effective and result in higher rates of retention in treatment, lower rates of drug use and lower rates of HIV risk. To test these hypotheses, the research team in Jakarta will recruit 300 injecting drug users as they enter treatment at the Drug Dependence Hospital and its five satellite programs. Following informed consent procedures, research staff will randomize participants to either the BDRC intervention or to treatment as usual. All subjects will be fuly assessed at baseline and months 3, 6, 9, and 12. The proposed work will be build on collaborations that have been established with the Indonesian Investigator Adhi Nurhidayat,MD during his NIDA INVEST Fellowship at University of Pennsylvania when he spent time with David Metzger, PhD and George Woody, MD. It will also extend findings from a WHO study on substitution therapy of opiates and HIV/AIDS that was completed by Riza Sarasvita, MS,MHS (former NIDA Humphrey Fellow at Johns Hopkins University) and her colleagues at The Drug Dependence Hospital Jakarta, Indonesia.

Conditions

HIV Risk Behaviors; Heroin Injection; Retention in Methadone Treatment

Keywords

drug abuse counseling; HIV risk reduction counseling; HIV infection; injection drug users; AIDS

Outcome Measures

Primary Outcomes (1)

• Injection drug use

  the primary endpoint will be the frequency of injection drug use during the 30 days prior to the final assessment at 12 months.

  one year

Secondary Outcomes (1)

• retention in methadone treatment

  one year

Study Arms (2)

Behavioral and Drug Risk Counseling

EXPERIMENTAL

Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.

Behavioral: Behavioral Drug and Risk Counseling (BDRC)

Treatment as Usual

ACTIVE COMPARATOR

Participants assigned to this arm will receive methadone treatment without and alterations.

Behavioral: methadone maintenance treatment

Interventions

Behavioral Drug and Risk Counseling (BDRC) BEHAVIORAL

The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as "contracts" and these contracts are reviewed and revised at each subsequent session.

Behavioral and Drug Risk Counseling

methadone maintenance treatment BEHAVIORAL

daily individualized doses of methadone will be provided by the program staff.

Treatment as Usual

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Enrollment in methadone maintenance treatment
• Injected heroin within past 30 days by self-report, documented by "tracks" or puncture marks
• or more years of age
• Meets DSM-IV criteria for opiates dependence with physiologic features
• Agrees to keep bi-weekly appointments if selected
• Current address within Jakarta and not planning to move
• Willingness and ability to give informed consent and otherwise participate
• Provision of adequate locator information

You may not qualify if:

• Clinically significant cognitive impairment, schizophrenia, paranoid disorder, bipolar disorder
• Advanced neurological, cardiovascular, renal, or other medical disorder that is likely to impair or make hazardous patient's ability to participate
• Physiologically dependent on alcohol, benzodiazepines or other sedative type drugs
• Concurrent participation in another treatment study
• Planning to enter inpatient or residential treatment within next year
• Pending legal charges with likely incarceration within next 12 months

Sponsors & Collaborators

• University of Pennsylvania: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

RSKO Drug Dependence Hospital

Jakarta, Timur, 13720, Indonesia

Location

MeSH Terms

Conditions

HIV Infections; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: May 23, 2011
• First Posted: May 25, 2011
• Study Start: May 1, 2009
• Primary Completion: January 1, 2015
• Study Completion: January 1, 2015
• Last Updated: August 17, 2016

Record last verified: 2011-05

Locations

ID (1)